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Abstract 
 
CLINICAL AND THERAPEUTIC SIGNIFICANCE OF OBESITY IN MELANOMA 
  
Jennifer McQuade, M.D., M.A..* 
 
Advisory Professor: Michael Davies, M.D., Ph.D. 
While the FDA approval of targeted and immune therapies in metastatic melanoma (MM) have 
dramatically improved outcomes in this disease, de novo and/or acquired resistance can limit 
the clinical benefit of these agents. The IGF-1/PI3K/AKT pathway has been implicated in 
resistance to both targeted and immune therapy. The IGF-1/PI3K/AKT pathway has also been 
shown to play a key role in the pathogenesis of obesity in other malignancies. To date, the 
impact of energy balance on clinical outcomes and therapeutic response in MM has not been 
studied. I hypothesized that energy balance would impact the molecular biology, behavior, 
and drug sensitivity of melanoma. 
 
The association of body mass index (BMI) with overall survival (OS) and progression-free 
survival (PFS) was studied in independent cohorts of >1900 MM patients treated with targeted 
therapy [dabrafenib and trametinib (D+T) and vemurafenib and cobimetinib], immunotherapy 
[ipilimumab and anti-PD-1/PDL-1], and chemotherapy. The functional significance of obesity 
was tested using a mouse model of diet-induced obesity (DIO) injected subcutaneously with 
murine melanoma cells. Tumors were followed for growth and assessed by proteomics and 
flow cytometry. The effect of DIO on therapeutic sensitivity was tested in tumor-bearing mice 
treated with a) D+T and b) anti-PD1.  
 
vi 
 
Obesity was associated with significantly improved PFS and OS in MM patients treated with 
both targeted therapy and immunotherapy but not chemotherapy. Improved outcomes were 
not attributable to differences in clinical prognostic factors or treatment-related adverse 
events. The association of BMI with improved outcomes was driven by markedly improved 
survival in obese compared to normal BMI males, whereas no significant associations were 
observed in females. In a subcutaneous model of mouse melanoma, DIO led to increased 
tumor growth, increased PI3K pathway activation, and decreased immune infiltrates. There 
were no differences in sensitivity to D+T or anti-PD1 between diets in this model. 
Obesity is associated with markedly improved outcomes in MM patients treated with 
targeted and immune therapies.  In a subcutaneous model of murine melanoma, DIO 
increased tumor growth, recapitulating clinical associations in early stage melanoma. The 
biological basis for the paradoxical association of obesity with improved outcomes in MM 
should be explored further.  
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Chapter 1: Background 
 
Metastatic melanoma is an aggressive disease with poor outcomes historically. 
However, the outcomes of patients with metastatic melanoma have improved dramatically 
with the FDA approval of MAPK pathway-directed targeted therapies and checkpoint 
inhibitor immunotherapies.(1-7) Despite these many new options, metastatic melanoma 
patient outcomes remain heterogeneous and many patients still succumb to this disease. An 
improved understanding of factors associated with clinical benefit from these treatments 
may improve their personalized use and provide new insights into mechanisms of 
resistance. In other malignancies, clinical metabolic phenotypes (obesity and the metabolic 
syndrome) have been shown to correlate with clinical outcomes.(8-13) In preclinical models, 
dietary manipulation impacts tumor growth and sensitivity to anti-cancer therapies.(14-18) 
However, the impact of energy balance on melanoma molecular signaling, immunology, and 
response to therapy is currently unknown.  
 
The treatment of metastatic melanoma  
Melanoma is the most deadly of the common skin cancers. While clinically localized 
melanoma is curable by surgical resection, melanoma that has metastasized is an aggressive 
disease. Outcomes in patients with metastatic melanoma have historically been poor as 
chemotherapy has only limited activity in this disease. However, the treatment landscape for 
patients with metastatic melanoma has dramatically improved with the FDA approval of 10 
new drugs and combination regimens since 2011. These new therapies are the result of 
advances in the understanding of the molecular biology and immunology of this disease.  
Nearly 50% of cutaneous melanomas have an activating V600E point mutation in 
BRAF (BRAFV600)(19) resulting in constitutive activation of the RAF/MEK/ERK MAPK pathway 
that promotes cell proliferation and survival.  Randomized phase III trials demonstrated that 
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vemurafenib and dabrafenib (both BRAF inhibitors) significantly improved ORR and PFS in 
BRAFV600 metastatic melanoma patients, leading to their approval.(2, 20) However, ~50% of 
patients failed to respond, and 10% of patients had disease progression as their best 
response, indicating the presence of de novo resistance.  In addition, the median duration of 
response was only ~6 months due to rapid development of acquired resistance.  Concurrent 
inhibition of BRAF and MEK can help overcome MAPK pathway reactivation, as demonstrated 
by the improvement in ORR (75%) and PFS (~10 months) with combined BRAF and MEK 
inhibition (dabrafenib + trametinib and vemurafenib + cobimetinib). (4, 5) However, responses 
remain variable, and most patients still go on to develop resistance.(21) 
The other major category of systemic therapies now approved in metastatic melanoma 
is immunotherapy. Melanoma has long been known to be a highly immunogenic tumor. High-
dose interleukin-2 (HD-IL2), a cytokine therapy, was FDA approved in 1998 in metastatic 
melanoma based on rare but durable responses.(22)  The newer immunotherapies are the 
checkpoint inhibitors which work by blocking the inhibitory checkpoints that limit T cell 
activation, effectively “taking the brakes off” the immune system to allow it to eradicate tumors. 
Anti-CTLA4 (Ipilimumab) was the first checkpoint inhibitor FDA approved in 2011.(1, 23) 
Though the response rate with ipilimumab is only 10-15%, these responses are extraordinarily 
durable. Subsequently, the anti-PD1 antibodies nivolumab and pembrolizumab have been 
FDA approved in metastatic melanoma (and other diseases). These agents have response 
rates ~40% in metastatic melanoma are much better tolerated than ipilimumab.(6, 24). 
However, while responses to checkpoint inhibitors are extremely durable, the majority of 
patients fail to respond, representing de novo resistance, and biomarkers to accurately predict 
response are lacking.   
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IGF1/PI3K/AKT signaling and therapeutic resistance 
  Oncogenic activation of the PI3K/AKT pathway is one of the most frequent events in 
cancer. The PI3K pathway can be activated by binding of ligands to receptor tyrosine kinases, 
including insulin-like growth factor receptor (IGF1R) and the insulin receptor (IR).  The Davies 
lab previously demonstrated that BRAFV600 melanoma cell lines with de novo resistance to 
BRAF and MEK inhibitors are characterized by increased expression of IGF1R and 
compensatory activation of the PI3K/AKT pathway following MAPK pathway inhibition (Figure 
1). (25, 26)  Both PI3K/AKT pathway activation and therapeutic resistance could be overcome 
by inhibition of IGF1, IGF1R, or AKT.  Increased activation of IGF1R was also identified in 
both cell lines and patient samples with acquired resistance to BRAF inhibitors.(27)  While 
combined inhibition of BRAF and MEK was able to slow growth of these cell lines, inhibition 
of IGR1R or PI3K was required to achieve cell death.(27)   
 We have also recently shown that the PI3K/AKT pathway can mediate resistance to 
immunotherapy. (28)  Loss of the tumor suppressor PTEN is one of the most common ways 
that the PI3K/AKT pathway is activated and occurs in ~30% of melanoma.(29)  In patients, 
loss of PTEN is correlated with decreased tumor infiltrating lymphocytes and worse outcomes 
with anti-PD1 immunotherapy. In preclinical models, PTEN loss decreases T cell trafficking 
into tumors and inhibits T cell-mediated tumor killing. (28)   
These and other studies support the rationale for combining PI3K pathway inhibition 
with MAPK pathway inhibition and/or checkpoint inhibitors. However, clinical development of 
IGF-1R/PI3K pathway inhibitors has been slow due to the challenge of achieving significant 
target inhibition at clinically tolerated doses.(30)  However, other less toxic strategies to inhibit 
this pathway could have benefit. 
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Energy balance and cancer  
Obesity and the metabolic syndrome are well-established risk factors for many 
malignancies, including breast, endometrial, colon, and pancreatic cancers.(31) In fact, 
obesity is now poised to overtake smoking as the leading preventable cause of cancer. 
Obesity has also been associated with increased recurrence risk and mortality in some 
malignancies.(11, 12) Based on strong epidemiological evidence, preclinical studies 
demonstrating increased tumor growth in obese models, and biological plausibility, energy 
balance has become a major target for cancer prevention efforts and identified as a priority 
area of research by the American Society of Clinical Oncology and the National Cancer 
Institute.(32) 
However, higher BMI has also been associated with improved survival in some 
cancers,(33-36) a phenomenon dubbed the “obesity paradox.” Whether this unexpected 
association is due to disease biology, ability to tolerate cytotoxic treatments, or other factors 
such as concurrent medication use for obesity-related comorbidities that may impact cancer 
biology (i.e. statins, metformin, beta blockers) remains unclear.  
 
Molecular and immunological effects of energy balance  
The biology underlying the impact of energy balance on cancer risk and progression 
is complex, and includes the stimulation of signaling pathways by obesity-related cytokines 
and hormones such as insulin-like growth factor 1 (IGF1) and leptin, chronic inflammation,  
increased oxidative stress, and adipocyte cross-talk.(37)  The insulin/IGF axis has been 
implicated as one of the key mediators in the relationship between obesity and cancer.(37, 
38) Insulin and IGFs regulate growth and metabolism at both the organism and tissue level. 
Obesity results in high circulating levels of these hormones, which are in turn linked to 
increased incidence and worse outcomes in several cancers.(39, 40) Diet-induced obesity 
(DIO) has been shown in preclinical models of many tumor types to promote cancer 
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development and progression as well as induce resistance to therapy, often in association 
with increased IGF1 and activation of the PI3K-AKT pathway.(14-18) Conversely, calorie 
restriction (CR) has been shown to suppress tumor growth and prolong survival.(18, 41-44) 
IGF1 appears to be a key mediator of many of these effects as knock-down of IGF1 attenuates 
the growth stimulatory effects of DIO and restoration of IGF1 abolishes the inhibitory effects 
of CR on tumor growth.(45, 46)  
Links between obesity, chronic inflammation, and cancer initiation have been 
described in many malignancies. Obesity has been demonstrated to negatively impair the 
adaptive immune response, with increased rate of vaccine failure in patients, and decreased 
cell-mediated immunity and immunological memory in DIO animal models.(47) However, the 
impact of energy balance on anti-tumor immunology remains largely unexplored and the 
impact of obesity on response to checkpoint inhibition has not been examined in any disease.  
 
Energy balance in melanoma 
The impact of energy balance in melanoma has not been well-studied to date. 
Limited data suggests that obesity is associated with a slightly increased risk of melanoma 
in men (48) and increased primary tumor Breslow thickness.(49)  However, the association 
of obesity with clinical outcomes in patients with melanoma had not been previously 
investigated. (31) The Lee lab at MD Anderson recently demonstrated that obesity is 
associated with worse outcomes in a large cohort of patients with surgically resected 
melanoma.(50)  In this study, we examined the association of body mass index (BMI) with 
overall survival and disease free survival in 1186 patients with surgically resected melanoma 
(75% Stage I/II, 24% Stage III, and 1% Stage IV). Obesity (BMI≥30) was associated with 
worse overall survival and disease free survival in this cohort, associations that remained 
significant after adjusting for sex, age, and disease stage. However, when serum C-reactive 
protein (CRP), a key marker of inflammation that has previously been associated with worse 
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prognosis in this population,(51) was added into the model, obesity was no longer 
significantly associated with survival but CRP was. This indicates that the association of 
obesity with poor outcomes in surgically resected melanoma may be mediated by chronic 
inflammation. While this study included patients of all stage of melanoma, the vast majority 
had clinically localized disease as this was a surgical cohort. Only 15 patients had Stage IV  
melanoma; therefore, this study was underpowered to examine the association of BMI with 
outcomes in Stage IV melanoma. Moreover, this cohort was accrued between 1998 and 
2008, which was before the FDA approval of contemporary targeted and immune therapy in 
melanoma and could therefore not be used to examine outcomes with these therapies.  
   In preclinical mouse models of B16 melanoma, diet-induced obesity has been 
shown to increase melanoma tumor growth and progression, however, the mechanisms are 
poorly understood.(52-54) Thus far, energy balance has not been studied in genetically 
relevant melanoma models (such as BRAF mutant), nor has the impact of energy balance 
on sensitivity to clinically relevant targeted or immune therapies. 
 
In summary, there is strong parallel evidence that (1) energy balance modulates the activity 
of the PI3K signaling pathway, and (2) activation of the PI3K signaling pathway can cause 
resistance to both targeted and immune therapy in melanoma (Figure 1).  I thus hypothesized 
that energy balance could impact the biology of melanoma and the efficacy of targeted therapy 
and immune therapy. To test this hypothesis, I assessed the association of BMI with overall 
survival (OS), progression-free survival (PFS), and overall-response rate (ORR) in multiple 
large independent cohorts of metastatic melanoma patients treated with targeted and immune 
therapies.  In addition, I conducted functional testing of the impact of obesity on melanoma 
tumor growth, molecular signaling, and therapeutic response in a genetically relevant, 
immunocompetent murine melanoma tumor model.   
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Figure 1: Molecular signaling in obesity and melanoma.   
The PI3K pathway plays a key role in both melanoma and energy balance signaling. Obesity 
results in increased circulating insulin and IGF-1 which bind to their cell surface receptors 
leading to downstream activation of the PI3K pathway. The PI3K pathway is also commonly 
activated in melanoma and can lead to resistance to both targeted and immune therapies.    
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Chapter 2: Methods 
 
Clinical cohorts 
Analysis was conducted on independent cohorts of patients with metastatic 
melanoma, including 2 trial cohorts of patients treated with BRAFi + MEKi targeted therapy 
combinations, a multi-institutional cohort of patients treated with PD-1 immunotherapy, a trial 
cohort of patients treated with ipilimumab immunotherapy + DTIC chemotherapy vs. DTIC 
alone, and a control arm of DTIC chemotherapy (Table 1).  
BMI at treatment initiation was calculated as weight (kilograms) divided by the 
square of height (in meters) and categorized according to standard World Health 
Organization definitions of underweight (BMI<18.5), normal weight (18.5-24.9), overweight 
(25-29.9), and obese (≥30).(55) Underweight patients were excluded from analyses due to 
low prevalence (<2%) across the cohorts.  
Patients were followed from the date of treatment initiation or baseline randomization 
until disease progression [progression-free survival (PFS)] or death (OS). Disease 
progression and response rate were defined by Response Evaluation Criteria in Solid 
Tumors (RECIST) 1.1 criteria.(56) Survival curves for OS and PFS across BMI category and 
by sex were generated using the Kaplan-Meier method. The association of BMI with 
prospective survival outcomes was evaluated in Cox proportional hazards regression 
models adjusted for prognostic factors. Logistic regression was used to assess associations 
of BMI with treatment response and pharmacokinetics. In all analyses, normal BMI was used 
as the reference category.(57) Statistical analyses were performed utilizing SAS 9.4, JMP 
(SAS), R studio, and S+ 8.0.  
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 Table 1: Metastatic melanoma patient cohorts 
Therapy Cohort Participants Men Women 
Targeted  
Therapy 
  D+T 599 347 252 
  V+C 240 143 97 
Immune  
Therapy 
  IPI + DTIC 207 138 69 
  PD1/PDL1 331 214 117 
Chemotherapy 
  DTIC 320 174 146 
  DTIC 221 140 81 
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In vivo experiments 
Cell lines 
BRAF-mutant murine melanoma cell lines were provided by Marcus Bosenberg from 
the Yale University Mouse Melanoma (YUMM) lines, Yale University.(58)   YUMM 3.1 cells 
(BrafV600E::Cdkn2a-/-) and YUMMM 5.2 (BrafV600E/wt p53−/−) cells were maintained in 
DMEM-F12 media with 10% FBS, 1% NEAA and 1% PS.   
 
Mice and diets 
Male C57/Bl6 18 week old diet-induced obesity (DIO) (#380050) and control mice 
(#380056) were obtained from Jackson laboratories. These mice have been fed either a 
60% high-fat diet (Research labs D12492, composition- 60% fat, 20% protein, 20% 
carbohydrates) or a low fat matched purified ingredient isocaloric diet (Research labs 
D12451, composition- 20% protein, 70% carbs, 10% fat) since weaning at 6 weeks. Mice 
were acclimatized for 3 weeks and continued on the same diets. All animal experiments 
were approved by The University of Texas MD Anderson Cancer Center Animal Care and 
Use Committee 
 
Mouse phenotypic analyses 
Mice were weighed weekly. Following overnight fasting, serum IGF-1 (R&D System) 
and IGFBP-1 (EMD Millipore) were measured by ELISA and blood glucose was measured 
by glucometer at baseline.   
 
Treatments 
1x106 cells YUMM 3.1 or YUMM 5.2 cells were injected subcutaneously into the left 
flank of 21 week DIO or control mice. Tumor-bearing mice were treated with twice weekly IP 
injections of 200mg/kg of anti-PD1 antibody (Bioxcell Clone RMP1-14) or isotype control 
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(Bioxcell Clone 2A3) or daily oral gavage treatment of dabrafenib (30mg/kg) and trametinib 
(1 mg/kg) or vehicle.  Tumors were measured every 3 days with calipers and tumor volume 
was calculated as the product of shortest length squared x longest length.  
 
 
Cell line protein isolation and western blotting 
Cells were plated in 6-well plates overnight. Cells were collected by scraping and 
washing 3x with cold PBS. The pellets were then lysed in buffer to isolate protein. Protein 
was quantified using the BCA reaction. Protein concentration was adjusted to 1.5mg/ml.   
Western blots of cell lines were performed for insulin receptor and IGF-1R (Cell Signal) with 
actin run to confirm equivalent protein loading between samples. For reverse phase protein 
array, cell lysate was mixed with 4 x SDS sample buffer and boiled for 5 minutes and then 
stored at -80.  
 
Tissue handling 
Day 14 tumor tissue was divided with 1/2 OCT-embedded, 1/4 FFPE, and 1/4 snap 
frozen. For each tumor sample used for protein extraction, a hematoxylin and eosin (H&E)-
stained slide was prepared and reviewed by a pathologist (M Tetzlaff). Regions containing 
80% or more viable tumor cells were identified. To isolate tumor tissue, the marked H&E 
slide was used to guide macrodissection of the matched tissue block.  
 
Reverse-phase protein array 
Extraction of protein from the dissected tumor samples was performed by the MD 
Anderson Functional Proteomics Core facility as previously described. (59) Reverse phase 
protein array (RPPA) analysis, which quantitatively measures >200 total- and phospho-
proteins in oncogenic signaling pathways, was performed as previously described.(60) A 
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detailed description of the RPPA method and data normalization is available at the core 
facility's web page. 1  
 
Immunohistochemistry 
FFPE tissue blocks were cut into 5-μm sections.  Immunohistochemistry for pS6 
(Clone D57.2.2E Cell Signaling, catalog #4858) was performed. Stained slides were 
reviewed by a pathologist (M.T. Tetzlaff) and an H-score was derived by multiplying the 
staining intensity (0, 1+, 2+, or 3+) by the percentage of positive cells. 
  
Flow cytometry 
Tumor tissues and spleens were weighed and dissociated into single cell 
suspensions. Erythrocytes in all samples were depleted using ammonium-chloride-
potassium lysing buffer (Invitrogen). Cells were treated with Fc blocking antibody and then 
stained with mAbs against CD8, CD4, Gr-1, CD11b, F4/80 and CD25. Samples were 
analyzed using FACS cantoII (BD Biosciences). 
 
Statistical analysis 
GraphPad Prism was used to perform statistical tests and graphing. A t-test was 
used to test for significance and data was plotted with standard error of the mean (SEM) 
shown. P values less than 0.05 were considered statistically significant.  Heatmaps were 
generated using Java Cluster and Tree View.  
  
1 https://www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-
core.html 
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Chapter 3: Association of BMI with outcomes in patients treated with targeted therapy 
 
Introduction 
Nearly 50% of cutaneous melanomas have an activating BRAFV600 mutation (19) 
resulting in constitutive activation of the RAF/MEK/ERK MAPK pathway that promotes cell 
proliferation and survival.  Treatments targeting the MAPK pathway have impressive activity 
in BRAFV600 mutant metastatic melanoma with response rates of >70% for both FDA-
approved BRAF + MEK combinations. However, not all patients respond and most go on to 
develop resistance.(21) Understanding the clinical factors associated with benefit from these 
therapies is critical to risk-stratifying patients and making informed treatment decisions.  
A key mechanism of resistance to MAPK pathway targeted therapy is PI3K pathway 
activation. This can occur at multiple nodes in this pathway, including via binding of receptor 
tyrosine kinases on the cell surface such as insulin and IGFR. Obesity results in higher 
circulating insulin and IGF-1, even in the absence of diabetes, and binding of these growth 
factors leads to downstream activation of the PI3K pathway. This interaction has been 
demonstrated in preclinical models in other malignancies to be key in the pathogenesis of 
obesity in promoting tumor growth and resistance to targeted therapy. (14-18, 61, 62)  Given 
this, I hypothesized that obesity would be associated with worse outcomes in patients with 
BRAFV600 melanoma treated with targeted therapy.  
Results 
Initial analysis was conducted on a cohort of treatment-naive patients with BRAFV600-
mutant metastatic melanoma treated with the BRAF inhibitor + MEK inhibitor combination 
dabrafenib and trametinib (D+T; FDA approval, 2014) in the randomized clinical trials 
BRF113220 (part C), COMBI-d, and COMBI-v with available BMI at treatment initiation 
(n=610).(4, 63-65)   
Eleven patients (1.8%) were underweight (BMI<18.5), 222 (37.1%) were normal 
weight (BMI 18.5-24.9), 231 (38.6%) were overweight (BMI 25-29.9), and 146 (24.4%) were 
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obese (BMI ≥30) (Figure 2). Clinical characteristics, including tumor burden, LDH, and 
ECOG PS were similar across BMI groups (Table 2). However, patients with higher BMI 
tended to be older, male, and less likely to have Stage M1C disease. As expected, obese 
patients were more likely to use metabolic syndrome-associated medications (metformin, 
statins, beta blockers, and aspirin). 
With a median follow-up of 20.2 months, the median PFS and OS were 9.6 and 19.8 
months, respectively, for normal BMI, 11.0 and 25.6 months for overweight, and 15.7 and 
33.0 months for obese patients treated with D+T (Figure 3).   Obese patients had 
significantly improved PFS (HR 0.73, 95% CI 0.56-0.95) and OS (HR 0.63, 95% CI 0.46-
0.86) compared to normal BMI patients (Table 3). Analysis of BMI as a continuous variable 
demonstrated a dose-dependent inverse relationship between BMI and HR for PFS that 
extended through morbid obesity (Figure 4).   
On multivariate analysis incorporating clinicopathological factors previously 
associated with outcomes with D+T(65) (age, sex, stage, LDH, BRAFV600 mutation type, 
ECOG PS, sum of target lesion diameters, number of disease sites, and prior adjuvant 
therapies), obesity remained associated with improved PFS (multivariate HR 0.75, 95% CI 
0.57-0.99) and OS (HR 0.59, 95% CI 0.43-0.82) (Table 3).  I also examined the possible 
contribution of metabolic syndrome related medication use, including metformin, beta 
blockers, aspirin, and statins as these medications may have potential anti-cancer activity. 
Following adjustment for concomitant medication use, obesity remained strongly associated 
with improved OS (multivariate HR 0.63, 95% CI 0.44-0.88), while the association with PFS 
was slightly attenuated (HR 0.77, 95% CI 0.58-1.03).  Exclusion of patients taking metformin 
(n=50) did not substantively change the association observed for obese BMI and OS (HR 
0.63, 95% CI 0.44 – 0.91).   
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Clinical response rates with D+T were also modestly increased in obese patients 
(OR 1.6, 95% CI 1.0-2.6) (Table 4) .Rates of adverse events were similar by BMI category 
(Table 4).  
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Figure 2: BMI distribution of D+T cohort.  
Histogram of BMI distribution shows a similar distribution to the general US population. <2% 
of patients were underweight and >60% were overweight or obese.  
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 Table 2: Baseline characteristics of patients treated with dabrafenib and trametinib 
(D+T) by BMI category 
 BMI at treatment initiation  
 
Characteristic 
Normal BMI  
(18.5 to <25) 
Overweight  
(25 to <30) 
Obese 
(≥30) 
Patients, No. (%) 222 (37.1) 231 (38.6) 146 (24.4) 
Age, Mean, y (range) 52 (18-91) 56 (22-82) 56 (30-82) 
Male, No. (%) 109 (49.1) 156 (67.5) 82 (56.2) 
Stage, No. (%)    
   III/M1a/M1b 71 (32.0) 81 (35.1) 59 (40.4) 
   M1c 151 (68.0) 150 (64.9) 87 (59.6) 
LDH, No. (%)a    
  >ULN 51 (23.2) 54 (23.4) 36 (24.7) 
  >2xULN 28 (12.7) 25 (10.8) 12 (8.2) 
BRAF mutation, No. 
(%) 
   
  V600E 201 (90.5) 192 (83.1) 129 (88.4) 
  V600K/V600E + 
V600K 
21 (9.5) 39 (16.9) 17 (11.6) 
ECOG PS, No. (%)b    
  0 159 (72.3) 168 (73.0) 103 (70.5) 
  ≥1 61 (27.7) 62 (27.0) 43 (29.5) 
Sum of lesion 
diameter, No. (%)c 
   
  <median (57mm) 101 (47.0) 117 (51.1) 72 (49.3) 
   ≥median (57mm) 114 (53.0) 112 (48.9) 74 (50.7) 
Number of organ 
sites with 
metastases, No. (%) 
   
  <3 112 (50.5) 114 (49.4) 82 (56.2) 
   ≥3 110 (49.5) 117 (50.6) 64 (43.8) 
Prior adjuvant 
ipilimumab, No. (%) 
2 (0.9) 3 (1.3) 4 (2.7) 
Prior non- ipilimumab 
adjuvant therapy, 
No. (%) 
26 (11.7) 25 (10.8) 14 (9.6) 
Concomitant 
medications, No. (%) 
   
  Metformin 8 (3.6) 13 (5.6) 29 (19.9) 
  Statin 24 (10.8) 27 (11.7) 39 (26.7) 
  Beta blocker 27 (12.2) 47 (20.3) 43 (29.5) 
  Aspirin 23 (10.4) 26 (11.3) 37 (25.3) 
aData missing for 2 patients. bData missing for 3 patients. cData missing for 9 patients
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Figure 3: Outcomes by BMI category in patients treated with D+T. A. Progression-free 
survival. B. Overall survival. Blue=obese. Green=overweight. Red=Normal BMI 
A 
 
PFS 
OS 
 
 
 
B 
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Table 3: Association between BMI and outcomes for patients treated with D+T 
aAdjusted for age, gender, stage, LDH, BRAF mutation, ECOG performance status, sum of 
target lesion diameters, number of disease sites, and prior adjuvant therapies 
 
  
 
 
BMI  
 
 
Patient 
No. (%) 
PFS OS 
 
Median 
(mo) 
Univariate 
Adjusted  
HR  
(95% CI) 
Multivariate 
Adjusted  
HR  
(95% CI)a 
 
Median 
(mo) 
Univariate 
Adjusted  
HR (95% 
CI) 
Multivariate 
Adjusted  
HR  
(95% CI) a 
18.5 
to <25 
222 
(37) 
9.6 1.00 1.00 19.8 1.00 1.00 
25 to 
<30 
231 
(39) 
11.0 0.90 (0.76-
1.19) 
0.95 (0.75-
1.21) 
25.6 0.84 (0.65-
1.10) 
0.78 (0.59-
1.02) 
≥30 146 
(24) 
15.7 0.73 (0.56-
0.95) 
0.75 (0.57-
0.99) 
33.0 0.63 (0.46-
0.86) 
0.59 (0.43-
0.83) 
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Figure 4: HR for PFS by BMI in patients treated with D+T. Spline analysis showing HR for 
PFS (y-axis) by BMI (x-axis). Solid line indicates HR with curve centered at reference BMI 24.9. 
Dotted lines indicate 95% CI.  
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Table 4: Clinical response rates and adverse events by BMI category in patients treated 
with D+T 
 
Outcome 
Normal BMI 
(18.5 to <25) 
Overweight 
(25 to <30) 
Obese 
(≥30) 
Response rate 64% 65% 77% 
  OR vs Normal BMI 
(95%CI)   OR 0.90 (0.61-1.34) OR 1.63 (1.0-2.63) 
Adverse events    
  Any AE 216 (98%) 226 (97%) 145 (>99%) 
  Grade III/IV AE 110 (50%) 125 (54%) 95 (65%) 
  AE leading to    
treatment 
discontinuation  28 (13%) 27 (12%) 30 (21%) 
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A cohort of patients treated with the only other FDA-approved BRAF inhibitor + MEK 
inhibitor combination for BRAFV600-mutant metastatic melanoma, vemurafenib and cobimetinib 
(V+C; FDA approval, 2016), in the phase III coBRIM randomized controlled trial (n=241), was 
analyzed as a validation cohort.(5, 66) Clinical characteristics are presented in Table 5. 
Obese patients treated with V+C again had improved PFS (HR 0.62, 95% CI 0.42-0.91) 
and OS (HR 0.64, 95% CI 0.41-0.98) compared to normal BMI patients, with hazard ratios very 
similar to those observed in the D+T cohort (Table 6).  Following adjustment for clinical 
prognostic factors in this smaller cohort (age, gender, stage, LDH, BRAF mutation, ECOG 
performance status), the hazard ratios were minimally changed but statistical significance was 
lost (PFS HR 0.66, 95% CI 0.42-1.02; OS HR 0.62, 95% CI 0.37-1.02).  
Pharmacokinetic data available for this cohort demonstrated no significant differences in 
serum Cobimetinib concentrations between BMI groups (Figure 5). 
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 Table 5: Baseline characteristics of patients treated with V+C by BMI category 
 BMI at treatment initiation  
 
Characteristic 
Normal BMI 
(18.5 to <25) 
Overweight 
(25 to <30) 
Obese 
(≥30) 
Patients, No. (%) 85 (35.4) 88 (36.7) 67 (27.9) 
Age, Median, y  
(25-75%) 50 (39-61) 59 (50-67) 57 (44-65) 
Male, No. (%) 40 (47.1) 59 (65.9) 44 (65.7) 
Stage, No. (%)    
   III/M1a/M1b 34 (40.0) 34 (38.6) 32 (47.8) 
   M1c 61 (60.0) 54 (61.4) 35 (52.2) 
LDH >ULN, No. (%)a 45 (46.4) 41 (47.7) 26 (40.0) 
BRAF mutation, No. 
(%)b 
   
  V600E 61 (91.0) 62 (86.1) 44 (84.6) 
  V600K 6 (9.0) 10 (13.9) 8 (15.4) 
ECOG PS, No. (%)c    
  0 65 (77.4) 72 (82.8) 43 (64.2) 
  ≥1 19 (22.6) 15 (17.2) 24 (35.8) 
a Data missing for 3 patients. b Data missing for 49 patients. c Data missing for 2 patients. 
 
 
 
 
 
 
Table 6: Association between BMI and outcomes for patients treated with V+C 
 
 
 
 
 
 
BMI  
 
 
Patient 
No. 
(%) 
PFS OS 
Univariate 
Adjusted  
HR (95% CI) 
Multivariate 
Adjusted  
HR (95% CI) 
Univariate  
Adjusted  
HR (95% CI) 
Multivariate 
Adjusted  
HR (95% CI)  
  All 
patients 
  (n=240)     
18.5-
24.9 
85 (35) 1 1 1 1 
25-29.9 88 (37) 0.73 (0.51-
1.04) 
0.65 (0.43-
1.00) 
0.86 (0.58-
1.28) 
0.67 (0.43-
1.06) 
≥30 67 (28) 0.62 (0.42-
0.91) 
0.66 (0.42-
1.02) 
0.64 (0.41-
0.98) 
0.62 (0.37-
1.02) 
Adjusted for age, sex, stage, and LDH 
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Figure 5: Pharmacokinetics by BMI category for Cobimetinib. No significant differences are 
seen in Cobimetinib serum pharmacokinetics by BMI category A. steady-state area under the 
curve (AUC) (p=0.39)   B. maximum concentration (Cmax) (p=0.34), and C.  minimum 
concentration (Cmin)  (p=0.37) 
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Sex differences in BMI and outcome associations with targeted therapy 
As female sex was previously shown to be independently associated with improved 
survival in the D+T cohort,(65) and as there were sex differences in BMI distribution (Table 1), 
associations in men and women were next assessed separately. These analyses showed that 
obesity was associated with markedly improved outcomes in male patients but that BMI was 
not associated with outcomes in females (Table 7 and Figure 6). Median PFS and OS were 7.4 
and 16.0 months respectively for normal BMI males, 10.1 and 21.3 months for overweight 
males, and 12.8 and 36.5 months for obese males  
Obese males had significantly improved PFS (0.69, 95% CI 0.49-0.99) and OS (HR 
0.46, 95% CI 0.30-0.70) versus normal weight males on univariate analysis, with differences in 
OS remaining significant after adjustment for other prognostic features (multivariate HR 0.44, 
95% CI 0.29-0.69) (Table 7).  These differences were marked, as the 2-year OS rate for obese 
males was 64% compared to 35% for normal BMI males (Figure 6 and Table 8). Obesity in 
males was also associated with improved response rates (ORR 76% vs. 58%, OR 2.26, 95% 
CI 1.20-4.26) (Table 8). In contrast, there were no significant differences in OS, PFS, or 
response rates by BMI in female patients treated with D+T (Tables 7 and 8).  
Similar differences by sex were observed in patients treated with V+C. Obesity was 
associated with markedly improved PFS (HR 0.44, 95% CI 0.26-0.74) and OS (HR 0.53, 95% 
CI 0.29-0.93) in male patients.  In contrast, no significant associations of BMI with outcomes 
were detected in female patients (Table 7). 
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Table 7: Outcomes by BMI stratified by sex for patients treated with targeted therapy 
 
 
 
Population 
 
 
BMI  
 
 
Patient 
No. 
(%) 
PFS OS 
Univariate 
Adjusted  
HR (95% CI) 
Multivariate 
Adjusted  
HR (95% CI) 
Univariate  
Adjusted  
HR (95% CI) 
Multivariate 
Adjusted  
HR (95% CI)  
D+T 
  Male 
  (n=347) 
18.5-
24.9 
109 
(31) 
1 1 1 1 
25-29.9 156 
(45) 
0.85 (0.63-
1.13) 
0.93 (0.69-
1.25) 
0.73 (0.53-
1.00) 
0.80 (0.57-
1.11) 
≥30 82 (24) 0.69 (0.49-
0.99) 
0.75 (0.52-
1.08) 
0.46 (0.30-
0.70) 
0.44 (0.29-
0.69) 
  Female 
  (n=252) 
18.5-
24.9 
113 
(45) 
1 1 1 1 
25-29.9 75 (30) 0.95 (0.65-
1.39) 
1.05 (0.69-
1.59 
0.84 (0.52-
1.35) 
0.65 (0.37-
1.13) 
≥30 64 (25) 0.74 (0.48-
1.12) 
0.83 (0.54-
1.29) 
0.89 (0.55-
1.45) 
0.93 (0.56-
1.55) 
V+C 
  Male 
  (n=143) 
18.5-
24.9 
40 (28) 1 1 1 1 
 25-29.9 59 (41) 0.69 (0.44-
1.07) 
0.62 (0.38-
1.03) 
0.82 (0.51-
1.35) 
0.67 (0.39-
1.15) 
 ≥30 44 (31) 0.44 (0.26-
0.73) 
0.59 (0.31-
1.08) 
0.53 (0.29-
0.93) 
0.68 (0.35-
1.29) 
  Female 
  (n=98) 
18.5-
24.9 
45 (46) 1 1 1 1 
 25-29.9 30 (31) 0.64 (0.35-
1.16) 
0.66 (0.27-
1.58) 
0.71 (0.34-
1.39) 
0.72 (0.27-
1.83) 
 ≥30 23 (23) 0.92 (0.50-
1.64) 
0.75 (0.37-
1.51) 
0.75 (0.35-
1.50) 
0.59 (0.25-
1.29) 
 
 
Table 8: ORR and 2 year survival by BMI stratified by sex for patients treated with D+T 
Cohort BMI ORR OR (95% CI) 2 year PFS  2 year OS 
  All patients 18.5-24.9 65% 1 27% 27% 
25-29.9 65% 0.9 (0.6-1.3) 29% 51% 
≥30 77%  1.6 (1.0-2.6) 36% 64% 
  Male  
   
18.5-24.9 58% 1 20% 35% 
25-29.9 65%  1.4 (0.8-2.3) 27% 46% 
≥30 76%  2.3 (1.2-4.3) 33% 64% 
  Female 18.5-24.9 72% 1 34% 60% 
25-29.9 63%  0.7 (0.4-1.2) 36% 61% 
≥30 78% 1.4 (0.7-2.9) 41% 65% 
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Figure 6: Outcomes by BMI stratified by sex for patients treated with D+T. A. Male 
progression-free survival. B. Female progression-free survival C. Male overall survival. D. 
Female overall survival. Red lines, normal BMI; Green lines, overweight; Blue lines, obese 
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 Discussion 
Obesity was unexpectedly associated with improved outcomes BRAF-mutant metastatic 
melanoma patients treated with the two BRAF and MEK inhibitor combinations approved in 
metastatic melanoma.  In the larger cohort of patients treated with dabrafenib and trametinib, 
these associations were independent of multiple clinical prognostic factors previously found to 
be predictive of benefit from this therapy.(65) In this cohort, I also examined concomitant 
medications as a possible confounder as obese patients were more likely to be taking multiple 
medications associated with the metabolic syndrome which may have anti-cancer activity. 
However, BMI effects were independent of use of aspirin, metformin, beta blockers, and 
statins. Treatment tolerance was also examined as a possible explanation, but the Grade III/IV 
adverse events were actually slightly higher in obese patients, though this was not time 
adjusted and as obese patients had better response they stayed on therapy longer. The 
vemurafenib + cobimetinib validation dataset, which was significantly smaller, showed similar 
associations of higher BMI and better outcomes on univariate analysis but significance was lost 
on multivariate analysis. Cobimetinib pharmacokinetic data was available for this cohort and 
there was no difference by BMI category by pharmacokinetics. 
As female sex was previously found to be associated with improved PFS in the 
dabrafenib + trametinib cohort(65), and as there are differences in BMI distribution and body 
composition by sex, I next looked at male and female patients separately. This analysis 
showed that in both cohorts, obesity was strongly associated with improved outcomes in males, 
but no BMI associations were observed in females.  
Interestingly, there has only been one prior study of the association of BMI with 
outcomes in patients treated with targeted therapy.(36) In this study of patients with renal cell 
carcinoma (RCC), higher BMI was also found to be associated with improved survival. 
However, the association of BMI with outcomes has not been evaluated in metastatic RCC 
patients treated with other therapies. Thus, it is unclear if this paradoxical association is specific 
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to targeted therapies, or whether higher BMI is generally prognostic in these diseases. 
Therefore, I next examined the association of BMI with outcomes in metastatic melanoma 
patients treated with checkpoint inhibitor immunotherapy.  
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 Chapter 3: Association of BMI with outcomes in patients treated with immunotherapy 
 
Introduction 
The association of BMI with outcomes in patients treated with immunotherapy has 
never been examined in any malignancy, as this form of therapy is very new with FDA 
approvals first occurring in melanoma (ipilimumab 2011; pembrolizumab and nivolumab both in 
2014). Non-small cell lung cancer was the first non-melanoma malignancy in which anti-PD1 
was approved in 2015, and they have now been approved in RCC, bladder cancer and head 
and neck cancer, with more approvals expected.  
While targeted therapy has a robust predictive biomarker for response (BRAF V600 
mutation), immunotherapy lacks a biomarker adequate to inform treatment decisions.(67)The 
most well-studied biomarker is tumor PD-L1 expression. However, PDL-1 expression is 
dynamic and thresholds vary by assay. More problematic is that PD-L1 expression does not 
adequately discriminate between patients who will or will not benefit. Though higher PD-L1 
expression enriches for responders, patients with no tumor PD-L1 expression may still respond 
and vice-versa. Thus, identifying other clinical and/or molecular predictors of response in 
critical.  
Interestingly, there is considerable cross-talk between molecular signaling pathways 
and the anti-tumor immune response.(68, 69) Our lab has recently shown that PI3K-AKT 
pathway can cause resistance to checkpoint inhibitor immunotherapy.(70) The success of 
targeted therapy may also in part depend on the immune response.(71) Thus, though 
immunotherapy and targeted therapy are fundamentally different modalities, there may be 
common factors underlying response and resistance.  However, if opposing associations of 
BMI and outcomes were seen between targeted and immune therapy, this factor could be used 
to help decide which form of therapy is used first-line in BRAF-mutant patients.  
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The impact of obesity on the anti-tumor immune response has not been well-studied.  
Obesity leads to chronic inflammation and this is another key mechanism linking obesity to 
cancer initiation and progression.(72, 73) Obesity has been demonstrated to negatively impair 
the adaptive immune response, with increased rate of vaccine failure in patients, and 
decreased cell-mediated immunity and immunological memory in animal models.(47) However, 
the impact of obesity on tumor immunology has not been explored. 
Therefore, I next examined the association of BMI with outcomes in patients treated 
with both anti-CTLA4 and anti-PD1 immunotherapy.  
 
Results 
Metastatic melanoma patients treated on the Phase III RCT CA 184-024 of ipilimumab 
(IPI, anti-CTLA-4, FDA approval 2011) + dacarbazine (DTIC) with available BMI (n=207) were 
analyzed.(23) In addition, a cohort of 335 metastatic melanoma patients treated with anti-PD-1 
(pembrolizumab, FDA approval 2014, n=250; nivolumab, FDA approval 2014, n=73) or anti-
PDL-1 (atezolizumab, n=8) antibodies at 4 centers in the USA and Australia with BMI at 
treatment initiation, clinical response assessment, and survival data available was analyzed. 
Patients initiated therapy between October 2009 and January 2016. Additional clinical 
characteristics extracted included age, sex, stage, tumor mutation, prior treatments, and 
immune-related adverse events (irAEs).  
 BMI distributions of both immunotherapy cohorts were similar to the targeted therapy 
cohorts. Patients with higher BMI were again older and more likely to be male, but there were 
otherwise no consistent differences between BMI categories (Table 9).  
With a median follow-up of 38.8 months, obesity was associated with improved PFS 
(HR 0.67, 95% CI 0.45-0.99) and OS (0.64, 95% CI 0.42-0.97) compared to normal BMI in 
patients treated with IPI + DTIC (Table 10 and Figure 7). These associations remained 
significant after adjustment for age, sex, stage, and LDH. Similar to targeted therapy, obesity 
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was associated with large improvements in outcomes in men, with 2 year OS of 40.6% in 
obese versus 17.8% in normal BMI males. Multivariate analysis confirmed significantly 
improved PFS (HR 0.55, 95% CI 0.32-0.93) and OS (HR 0.40, 95% CI 0.22-0.72) in obese 
males. In contrast, BMI was not associated with either PFS or OS in females treated with IPI + 
DTIC (Table 10 and Figure 7). 
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Table 9: Patient characteristics of patients treated with immunotherapy 
 IPI + DTIC PD1 
  BMI  
18.5-24.9  
No. (%) 
BMI  
25-29.9 
No. (%) 
BMI 
 ≥30 
No. (%) 
 BMI  
18.5-24.9  
No. (%) 
BMI  
25-29.9 
No. (%) 
BMI 
 ≥30 
No. (%) 
Patients, No. 
(%) 
68 (33) 88 (43) 51 (25) 102 (31) 109 (33) 120 (36) 
Age, Mean, y 
(range) 
53 
 (24-83) 
60  
(31-87) 
60  
(34-80) 
57  
(18-86) 
63  
(34-86) 
63  
(22-86) 
Male, No. (%) 41 (60) 64 (73) 33 (65) 58 (57) 70 (64) 83 (69) 
Stage       
   III/M1a/M1b 17 (25) 38 (43) 26 (51) 19 (19) 32 (29) 40 (33) 
   M1c 51 (75) 50 (57) 25 (49) 81 (79) 76 (70) 80 (67) 
LDH >ULN,  
No. (%) 
26 (38) 31 (35) 18 (25) 40 (39) 38 (35) 39 (32) 
ECOG PS 
  0 46 (68) 65 (74) 35 (69) 60 (59) 64 (59) 72 (60) 
  ≥1 22 (32) 23 (26) 16 (31) 41 (40) 45 (41) 48 (40) 
Mutation status 
  BRAF mutant - - - 34 (33) 32 (29) 34 (28) 
    V600E - - - - - - 
    Other V600 - - - - - - 
  NRAS mutant   - - - 24 (24) 21 (19) 18 (15) 
  WT - - - 37 (36) 50 (46) 67 (57) 
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Table 10: Association between BMI and outcomes for patients treated with IPI + DTIC 
 
 
 
Population 
 
 
BMI  
 
 
Patient 
No. 
(%) 
PFS OS 
Univariate 
Adjusted  
HR (95% 
CI) 
Multivariate 
Adjusted  
HR (95% CI) 
Univariate  
Adjusted  
HR (95% CI) 
Multivariate 
Adjusted  
HR (95% CI)  
  All 
patients 
  (n=207)     
18.5-
24.9 
68 (28) 1 1 1 1 
25-29.9 88 (37) 0.87 (0.62-
1.22) 
0.88 (0.61-
1.26) 
0.76 (0.53-
1.08) 
0.70 (0.48-
1.03) 
≥30 51 (21) 0.67 (0.45-
0.99) 
0.63 (0.41-
0.95) 
0.64 (0.42-
0.97) 
0.54 (0.34-
0.86) 
  Male 
  (n=138) 
18.5-
24.9 
41 (29) 1 1 1 1 
25-29.9 64 (45) 0.76 (0.50-
1.16) 
0.77 (0.49-
1.22) 
0.69 (0.45-
1.07) 
0.63 (0.39-
1.01) 
≥30 33 (23) 0.53 (0.32-
0.88) 
0.55 (0.32-
0.93) 
0.46 (0.27-
0.80) 
0.40 (0.22-
0.72) 
  Female 
  (n=69) 
18.5-
24.9 
27 (28) 1 1 1 1 
25-29.9 24 (24) 1.02 (0.56-
1.88) 
1.29 (0.66-
2.51) 
0.79 (0.42-
1.50) 
0.84 (0.43-
1.64) 
≥30 18 (18) 1.02 (0.55-
1.92) 
0.92 (0.45-
1.86) 
1.13 (0.58-
2.18) 
1.16 (0.55-
2.46) 
Adjusted for age, gender, stage, LDH, and ECOG performance status 
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Figure 7. Outcomes by BMI in metastatic melanoma patients treated with Ipilimumab 
(IPI) + dacarbazine (DTIC).  A. All patients’ progression-free survival. B. All patients overall 
survival C. Male overall survival. D. Female overall survival. E. Male progression-free survival. 
F. Female progression-free survival. Red lines, normal BMI; Green lines, overweight; Blue 
lines, obese 
Female OS Male OS 
Male PFS Female PFS 
A B 
C D 
E F 
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Anti-PD1 
Increased BMI was again associated with significantly improved outcomes in males but 
not females treated with anti-PD-1/PD-L1.  For male patients, the 2 year PFS rate was 36% for 
overweight/obese versus 18% for normal BMI (HR 0.62, 95% CI 0.43-0.89) (Table 11 and 
Figure 8). Overweight/obese male patients also had improved OS (HR 0.60, 95% CI 0.41-0.90) 
(Table 11) and modestly improved response rates (45% vs 32%, OR 1.82, 95% CI 0.94-3.50) 
(Tables 12) In contrast, women treated with anti-PD-1/PD-L1 had identical response rates by 
BMI category (41%), and there were no significant BMI associations with PFS or OS (Table 12 
and Figure 8). 
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 Table 11: PFS and OS by BMI for patients treated with PD-1/PD-L1 
 
 
 
Population 
 
 
BMI  
 
 
Patient 
No. 
(%) 
PFS OS 
Univariate 
Adjusted  
HR (95% 
CI) 
Multivariate 
Adjusted  
HR (95% CI) 
Univariate  
Adjusted  
HR (95% CI) 
Multivariate 
Adjusted  
HR (95% CI)  
  All 
patients   
  (n=331)   
18.5-
24.9 
102 
(31) 
1 1 1 1 
≥25  229 
(69) 
0.77 (0.58-
1.02) 
0.86 (0.63-
1.16) 
0.72 (0.52-
1.00) 
0.75 (0.53-
1.07) 
  Male 
  (n=214) 
18.5-
24.9 
57 (27) 1 1 1 1 
≥25 157 
(73) 
0.62 (0.43-
0.89) 
0.66 (0.45-
0.96) 
0.60 (0.41-
0.90) 
0.68 (0.44-
1.04) 
  Female 
  (n=117) 
18.5-
24.9 
45 (38) 1 1 1 1 
≥25 72 (62) 1.07 (0.67-
1.68) 
1.20 (0.73-
1.97) 
0.90 (0.52-
1.56) 
0.85 (0.46-
1.56) 
 
 
 
 
 
Table 12: Clinical response rates by BMI for patients treated with PD-1/PD-L1 
 BMI<25 BMI≥25 
All patients 
Response rate 34% 44% 
  OR vs BMI<25 (95%CI)   OR 1.5 (0.9-2.4) 
Males 
Response rate 32% 45% 
  OR vs BMI<25 (95%CI)   OR 1.8 (1.0-3.5) 
Females 
Response rate 41% 41% 
  OR vs BMI<25 (95%CI)   OR 1.0 (0.5-2.1) 
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Figure 8. Outcomes by BMI in metastatic melanoma patients treated with PD1/PDL1.  A. 
All patients progression-free survival. B. All patients overall survival C. Male overall survival. D. 
Female overall survival. E. Male progression-free survival. F. Female progression-free survival. 
Red lines, normal BMI; Green lines, overweight; Blue lines, obese 
  
Overall PFS Overall OS 
Male OS Female OS 
Male PFS Female PFS 
A B 
C D 
E F 
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Discussion 
Consistent with the association of obesity with improved outcomes seen with targeted 
therapy, higher BMI was also associated with improved outcomes in patients treated with both 
anit-CTLA4 and anti-PD1/PDL1 immunotherapy. Moreover, there was again a large sex 
difference in BMI associations with very strong associations of higher BMI with improved 
outcomes seen in males and no associations observed in females.  Future work should focus 
on validating the findings of the PD1 cohort which was an off-protocol cohort and examining 
combination CTLA4 and PD1 therapy. These findings also support the rationale for examining 
the association of BMI with outcomes in other diseases in which immunotherapy has been 
approved. 
As noted in the introduction, the impact of obesity on anti-tumor immunity has not been 
previously studied. The work from the Lee lab showing that the association of higher BMI with 
worse outcomes in early stage melanoma was lost when serum C-reactive protein was added 
into the model suggests that inflammation may mediate the deleterious relationship between 
obesity and outcomes seen in clinically localized melanoma.(50) However, this chronic 
inflammation could hypothetically be beneficial in the setting of immunotherapy.  
Given that obesity was associated with improved outcomes in metastatic melanoma 
patients treated with both targeted and immune therapy, it was important to examine whether 
obesity was simply prognostic in advanced melanoma or if the effect was specific to these 
therapies.  
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 Chapter 4: Association of BMI with outcomes in patients treated with chemotherapy 
 
Introduction 
Metastatic melanoma is relatively resistant to chemotherapy and there is only one 
chemotherapeutic that has been approved in this disease, dacarbazine (DTIC). The ORR with 
DTIC is 5-10% and the median PFS is <2 months.(2, 23)  
The reason why melanoma is so chemo-resistant is not well understood.(74) The 
rewiring of molecular pathways that were purported to make melanoma “bullet-proof” are not 
unique to this disease. There are clinical factors associated with outcome in patients with 
melanoma treated with chemotherapy including age, sex, stage, and LDH. However, these are 
prognostic factors rather than predictive to this specific therapy. Given the very low activity of 
chemotherapy in melanoma, the association of BMI with outcomes in metastatic melanoma 
patients with chemotherapy can be used to approximate the impact of obesity on the natural 
history of this disease.    
Thus, I next examined the associations of BMI in metastatic melanoma patients treated 
with DTIC, a control arm in multiple RCTs(2, 23)  to explore whether BMI was prognostic in 
metastatic melanoma or if the effect was specific to targeted and immune therapy.  
 
Results 
Metastatic melanoma patients with available BMI data treated with dacarbazine (DTIC) 
in the control arms of CA 184-024(23) (n=221) and the Phase III BRIM3 randomized controlled 
trial (2) (n=309) were analyzed. Clinical characteristics of patients treated with DTIC are shown 
in Table 13.  
BMI was not significantly associated with PFS (CA 184-024, HR 0.83, 95% CI 0.59-
1.18; BRIM-3, HR 0.86, 95% CI 0.62-1.18) or OS (CA 184-024, HR 0.95, 95% CI 0.66-1.37; 
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BRIM-3, HR 0.94, 95% CI 0.62-1.41) in either cohort (Table 14, Figure 9).  Further, BMI was 
not significantly associated with outcomes in either males or females. Importantly, CA 184-024   
randomized patients to DTIC alone or DTIC + IPI which allowed me to statistically examine 
treatment interaction. In the OS analysis, the pinteraction for BMI, treatment, and sex was 0.035, 
indicating that BMI associations were sex- and treatment-specific.  
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 Table 13: Characteristics of patients treated with dacarbazine (DTIC) 
 
Characteristic 
DTIC (CA 184-024, n=320) DTIC (BRIM3, n=221) 
BMI 
18.5-24.9 
No. (%) 
BMI 
25-29.9 
No. (%) 
BMI 
≥30 
No. (%) 
BMI 
18.5-24.9 
No. (%) 
BMI 
25-29.9 
No. (%) 
BMI 
≥30 
No. (%) 
Patients, No. 
(%) 
143 (45) 107 (33) 70 (22) 74 (33) 88 (40) 59 (27) 
Age, Mean, y 
(range) 
49 (17-
86) 
56 (22-
84) 
53 (31-
78) 
55 (23-
83) 
60 (24-
88) 
56 (32-88) 
Male, No. (%) 70 (49) 73 (68) 31 (44) 38 (51) 66 (75) 36 (61) 
Stage, No. (%) 
   III/M1a/M1b 42 (29) 29 (27) 31 (44) 24 (32) 37 (42) 33 (56) 
   M1c 101 (71) 78 (73) 39 (56) 50 (68) 51 (58) 26 (44) 
LDH >ULN,  
No. (%)a 
68 (48) 44 (41) 23 (33) 37 (50) 36 (41) 23 (39) 
ECOG PS, No. (%) 
  0 95 (66) 77 (72) 46 (66) 55 (74) 63 (72) 38 (64) 
  ≥1 48 (34) 30 (28) 24 (34) 19 (26) 25 (28) 21 (36) 
Mutation, No. (%)b 
  BRAF mutant 143 (100) 107 (100) 70 (100) - - - 
    V600E 132 (92) 94 (88) 62 (89) - - - 
    Other V600 8 (5) 10 (9) 5 (7) - - - 
aData missing for 1 patient in DTIC-G cohort. bSpecific BRAF mutation data (V600E vs other 
V600) missing for 9 patients in DTIC cohort. 
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Table 14: Outcomes for patients treated with dacarbazine (DTIC) 
 
 
 
Population 
 
 
BMI  
 
 
Patient 
No. 
(%) 
PFS OS 
Univariate 
Adjusted  
HR (95% 
CI) 
Multivariate 
Adjusted  
HR (95% 
CI) 
Univariate  
Adjusted  
HR (95% 
CI) 
Multivariate 
Adjusted  
HR (95% 
CI)  
DTIC (BRIM3)a 
  All 
patients  
  (n=320)    
18.5-
24.9 
143 
(45) 
1 1 1 1 
25-29.9 107 
(33) 
0.93 (0.70-
1.23) 
0.94 (0.70-
1.25) 
1.05 (0.79-
1.39) 
0.98 (0.73-
1.31) 
≥30 70 (22) 0.86 (0.62-
1.25) 
0.91 (0.64-
1.26) 
0.92 (0.66-
1.28) 
0.94 (0.66-
1.32) 
  Male 
  (n=174) 
18.5-
24.9 
70 (40) 1 1 1 1 
25-29.9 73 (42) 0.87 (0.61-
1.25) 
0.91 (0.63-
1.32) 
1.09 (0.76-
1.57) 
0.97 (0.66-
1.41) 
≥30 31 (18) 0.75 (0.46-
1.20) 
0.73 (0.43-
1.17) 
1.05 (0.64-
1.68) 
0.92 (0.56-
1.51) 
  Female 
  (n=146) 
18.5-
24.9 
73 (29) 1 1 1 1 
25-29.9 34 (23) 0.97 (0.60-
1.53) 
0.84 (0.49-
1.40) 
1.00 (0.61-
1.60) 
0.85 (0.50-
1.40) 
≥30 39 (27) 0.97 (0.60-
1.53) 
1.02 (0.63-
1.65) 
0.82 (0.51-
1.29) 
0.94 (0.57-
1.52) 
DTIC (CA 184-024)b 
  All 
patients  
  (n=221)    
18.5-
24.9 
74 (33) 1 1 1 1 
25-29.9 88 (40) 0.73 (0.52-
1.01) 
0.81 (0.58-
1.14) 
0.85 (0.61-
1.19) 
0.91 (0.64-
1.28) 
≥30 59 (27) 0.83 (0.59-
1.18) 
0.96 (0.67-
1.39) 
0.95 (0.66-
1.37) 
1.16 (0.79-
1.70) 
  Male 
  (n=140) 
18.5-
24.9 
38 (27) 1 1 1 1 
25-29.9 66 (47) 0.62 (0.41-
0.94) 
0.77 (0.50-
1.18) 
0.72 (0.48-
1.10) 
0.89 (0.58-
1.36) 
≥30 36 (26) 0.70 (0.44-
1.12) 
1.06 (0.63-
1.78) 
0.97 (0.60-
1.56) 
1.55 (0.91-
2.66) 
  Female 
  (n=81) 
18.5-
24.9 
36 (44) 1 1 1 1 
25-29.9 22 (27) 1.08 (0.62-
1.90) 
1.13 (0.63-
2.01) 
1.06 (0.60-
1.88) 
1.29 (0.70-
2.36) 
≥30 23 (28) 1.04 (0.61-
1.77) 
1.02 (0.58-
1.77) 
0.88 (0.50-
1.55) 
0.91 (0.51-
1.64) 
aAdjusted for age, gender, stage, LDH, mutation,  and ECOG performance status.  bAdjusted 
for age, gender, stage, LDH, and ECOG performance status 
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Figure 9. Outcomes by BMI in metastatic melanoma patients treated with DTIC.  A. All 
patients progression-free survival. B. All patients overall survival C. Male overall survival. D. 
Female overall survival. E. Male progression-free survival. F. Female progression-free survival. 
Red lines, normal BMI; Green lines, overweight; Blue lines, obese 
 
A B 
C D 
E F 
Overall PFS Overall OS 
Male OS Female OS 
Male PFS Female PFS 
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Discussion 
In contrast to the results observed with targeted and immune therapy, BMI was not 
associated with outcomes in patients treated with chemotherapy. Interestingly, in some other 
malignancies, obesity has been associated with improved survival and one posited mechanism 
is via improved metabolic reserve in obese patients to allow them to better withstand 
chemotherapy which commonly causes anorexia, weight loss, nausea and vomiting, and 
diarrhea.(75) In contrast, in metastatic melanoma the paradoxical association is observed in 
patients treated with immunotherapy and targeted therapy which do not commonly cause 
weight loss, and not in those treated with chemotherapy. 
One potential explanation for why a BMI association is not seen with chemotherapy is 
that the activity is so low that it would in essence be difficult to “move the needle.” However, the 
activity of ipilimumab is low as well and in males treated with that therapy, the multivariable HR 
for overall survival was 0.4. Moreover, a test for interaction in the trial that randomized patients 
to ipilimumab + DTIC vs DTIC alone, a 6-way interaction for BMI, sex, and treatment was 0.35, 
supporting that these effects are predictive of response to contemporary therapies and not 
merely prognostic.   
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Chapter 5: Functional characterization of obesity in preclinical models of melanoma 
 
Introduction 
In order to functionally test the impact of obesity on melanoma tumor, I utilized a mouse 
model of diet-induced obesity. This model, in which male C57/Bl6 mice are fed a 60% high-fat 
diet, is well-validated in the literature and commonly used to test the impact of obesity on 
cancer initiation and progression.(76, 77) Compared to age-matched controls who have been 
fed a matched purified ingredient low-fat diet, diet-induced obesity (DIO) mice have higher body 
weight and adiposity by body composition analysis, as well as altered levels of obesity related 
cytokines such as insulin, IGF-1, leptin, and adiponectin. In other cancers, this model has been 
used to show that system-level metabolism can affect tumor biology and lead to increased 
tumor growth.(14-16, 78) Previously, models of B16 melanoma had demonstrated that diet-
induced obesity can increase melanoma tumor growth and progression though the mechanism 
has not been worked out. (52-54) Moreover, B16 melanoma is not a genetically relevant model 
with a defined driver mutation. Newer models now exist that are based on the driver mutations 
found in metastatic melanoma, specifically the BRAF mutation.  
Thus, in order to test the impact of energy balance in melanoma, I used a BRAF-mutant 
mouse melanoma cell lines injected into DIO and control mice. As the hypothesis was that 
energy balance would impact melanoma tumor growth and therapeutic sensitivity via the PI3K 
pathway, cell lines were chosen that were PTEN intact so that the PI3K pathway would not be 
constitutively activated.  As this model was BRAF-mutant and was in an immunocompetent 
mice, I was also able to examine the effect of obesity on response to both MAPK-pathway 
directed targeted therapy and immune therapy.  
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Results 
Cell line characterization 
Two BRAF mutant, PTEN intact mouse melanoma cell lines were obtained from the lab of Dr. 
Marcus Bosenberg at Yale University, YUMM 3.1 (BrafV600E::Cdkn2a-/-) and YUMM 5.2 
(BrafV600E::Cdkn2a+/-::p53-/-).  Reverse-phase protein array (RPPA) was performed on 
protein lysates extracted from the cell lines to quantitatively measure the expression levels of 
217 total- and phospho-proteins. Using a paired t-test with a cut-off of p<0.05, 141 proteins 
were identified which were differentially expressed between the two cell lines (Figure 10A).  To 
further drill down on the most significantly changed proteins, I introduced a new filter and 
examined those proteins with a fold change in mean protein expression >2.0 and identified 38 
differentially expressed proteins (Figure 10B). This analysis revealed Yumm 3.1 has significant 
higher expression of insulin-like growth factor (p<0.0001, average ratio YUMM 3.1/YUMM 5.2 = 
2.6) and insulin receptor (IR) (p<0.001, average ratio YUMM 3.1/YUMM 5.2 = 2.4) compared to 
YUMM 5.2. To validate these findings, I next performed western blot for IR and IGF1-R using 
the cell line Mel624 as a positive control and A375 as a negative control for IGF1-R. This 
analysis confirmed that YUMM 3.1 had high levels of both IR and IGF1-R and YUMM 5.2 had 
low levels (Figure 11).  
  
47 
 
  
 
 
  
A 
B 
B 
Y3.1   Y5.2 
48 
 
 Figure 10. YUMM 3.1 and YUMM 5.2 cell line reverse phase protein array 
Supervised clustering of RPPA data of 217 proteins in YUMM3.1 and YUMM 5.2 cell lines. A. 
Using a threshold of p<0.05, 141 proteins were identified which differentially expressed 
between the two cell lines. B. Applying an additional filter of > 2-fold change in mean protein 
expression between the two lines identified 38 proteins that were the most differentially 
expressed. Blue=decreased expression. Yellow=increased expression.  
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Figure 11. Western blot for IR and IGF1R 
Western blotting for IR on left and IGF1-R demonstrating high levels of both proteins in YUMM 
3.1 cells. Y3.1=YUMM 3.1, Y5.2=YUMM 5.2, 375=A375 (negative control), 624=Mel 624.   
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 Mouse model characterization 
Mouse models of diet-induced obesity (DIO) and matched control mice were obtained 
from Jackson laboratories. Male C57/Bl6 mice are fed a 60% high fat diet (Research Diets Inc) 
since weaning at 6 weeks of age to produce a validated DIO phenotype.(77)  Control mice of the 
same background were fed a matched purified ingredient 10% fat diet (Research Diets Inc). 18 
week old DIO and control mice were received and then acclimated for 3 weeks before 
experiments were started. Throughout the experiment, they were continued on the same diets 
as fed at Jackson laboratories.    
In order to characterize and validate the metabolic phenotypes of the DIO vs control 
mice, baseline body weight, and fasting serum IGF-1, IGFBP-1 and glucose were measured 
(Figure 12). DIO mice were found to have significantly higher body weight (DIO 39.5 g vs. 
control 28.1 g, p<0.001) serum IGF-1 (DIO 454.5 ng/ml vs. control 322.6 ng/ml, p<0.001), and 
fasting glucose (DIO 153.8 mg/dl, vs. control 120.9 mg/dl, p=0.01) and lower IGFBP-1 (DIO 6.7 
ng/ml vs. control 25.3 ng/ml. p=0.0029). These values are consistent with the published 
literature on this model and indicate the expected phenotypes were achieved.   
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Figure 12. Baseline metabolic characteristics of DIO and control mice.   
DIO mice have higher A. body weight, B. serum IGF-1, and C. fasting glucose and lower D. 
IGFBP-1 compared to control mice.  
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 Tumor growth experiments 
In the initial pilot study on melanoma tumor growth, 21 week old DIO and control mice 
were injected subcutaneously into the left flank with 1x106 YUMM 3.1 cells or YUMMM 5.2 
murine melanoma cells. Tumor size was measured 3X weekly and followed until tumor size 
reached 1.5 cm, or mice became moribund and were sacrificed. DIO increased tumor growth in 
both the YUMM 3.1 (Day 15 tumor size DIO 1059 ± 146 mm3 vs. control 282 ± 86 mm3, p=0.01) 
and YUMM 5.2 models (DIO 717.2 ± 229 mm3 vs control 62.13 ± 62.13 mm3, p=0.04) (Figure 
13).  As tumor growth was more consistent in the YUMM 3.1 model and our cell line 
characterization had shown that this line had higher levels of IR and IGF-R, follow-up studies 
were conducted with this model. A validation study conducted in 10 DIO and 10 control mice 
showed that tumors grew faster in DIO mice, with significantly greater day 14 tumor weight 
(p=0.012)  (Figure 14). 
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YUMM 3.1 
YUMM 5.2 
Figure 13. Tumor growth in DIO vs. control mice 
1.0 x 106 cells were injected subcutaneously into the flank of DIO or control mice.  
Increased tumor growth was observed in the DIO mice with both a. YUMM 3.1 cells 
and b. YUMM 5.2 cells 
A 
B 
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Figure 14. Tumor growth in DIO vs. control mice with YUMM 3.1 model.  DIO led to 
increased day 14 tumor weight (p=0.012).    
  
Days 
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 Molecular and immunological correlates of obesity 
On reverse phase protein array analysis comparing the tumor samples from the DIO 
xenografts to those of the control mice, there were significant differences in 99 of the 298 
proteins assessed, demonstrating that obesity impacts the molecular biology of melanoma 
(Figure 15A). Two of the most differentially expressed proteins were pS6 residues, highly 
sensitive markers of PI3K pathway activation (Figure 15B). This was confirmed by 
immunohistochemistry (Figure 15C). Significant differences were also seen in pAMPK, a key 
marker of cellular metabolism, between the DIO and control mice (Figure 15B). 
By flow cytometry, there was decreased immune infiltration in DIO xenografts compared 
to the control mice. However, there were no significant differences in spleen immunocytes 
indicating that this was specific to tumor infiltration and not a global decrease in immune 
populations (Figure 16).  
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Figure 15. Diet induced obesity and melanoma molecular signaling.   
A. Heat map shows 99 proteins differentially expressed between DIO and control mice. B. pS6 
residues significantly increased and pAMPK significantly decreased in DIO vs. control mice. C. 
Immunohistochemistry of representative samples demonstrating increased pS6 staining in DIO 
tumor samples.   
  
DIO Control 
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 Figure 16 Effects of DIO on immune cell populations.  
A. Tumors from DIO mice exhibit decreased CD8, CD4, MDSC, and CD4/25 cells. B. splenic 
immunocytes do not differ by dietary group  
 
  
A B 
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Therapeutic response 
Finally, I examined the impact of DIO on response to targeted and immune therapy in 
the subcutaneous YUMM 3.1 model. 21 week old DIO and control mice were injected 
subcutaneously into the left flank with 1x106 YUMM 3.1 cells murine melanoma cells. When 
tumors were measurable in >75% of mice, treatments were started.  
In the first experiment, mice were treated with twice weekly IP injections of anti-PD1 
antibody or vehicle control. Tumors in both the DIO and control mice were resistant to PD1 
immunotherapy with no tumor regression seen in either model and there was no significant 
difference in tumor kinetics (Figure 17 A&B).  
In the next experiment, mice were treated with daily oral gavage of either dabrafenib + 
trametinib or vehicle control.  Tumors in both the DIO and the control mice were rapidly 
eradicated by the targeted therapy combination, again with no significant differences by diet 
group (Figure 17 C and D) 
 
Discussion 
In a genetically relevant subcutaneous mouse melanoma model, diet-induced obesity 
increases melanoma tumor growth.  Importantly, the phenotype of the mice was validated prior 
to initiating therapy and I demonstrated that these mice did have higher fasting glucose and 
IGF-1 in addition to higher body weight.  Tumors from DIO mice exhibited increased PI3K 
pathway activation and decreased pAMPK, consistent with the initial hypothesis. Interestingly, 
the tumors of the DIO mice had decreased tumor infiltrating immune cells. To my knowledge, 
this is the first time that RPPA and tumor flow cytometry have been used to examine the 
molecular and immunological impact of obesity. These studies support the clinical association 
of higher BMI with worse outcomes in patients with early stage melanoma. To definitively 
demonstrate that PI3K pathway activation underlies this relationship, future studies should 
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examine whether the effect of DIO can be abolished with PI3K inhibitors, fasting, and/or fasting 
mimetics.   
In this subcutaneous model, there were no differences in sensitivity to either PD1 
immunotherapy or dabrafenib + trametinib targeted therapy.  This cell line (YUMM 3.1) was 
resistant to immunotherapy and exquisitely sensitivity to combination targeted therapy which 
makes it very difficult to be able to show differences in sensitivity to therapy between two 
organism metabolic phenotypes. Further, this subcutaneous model may not reflect the biology 
of metastatic melanoma. Finally, the implantation of a tumor into a host that has been fattened 
for 15 weeks may not reflect the biology of a tumor that develops in a patient with a lifetime of 
obesity.  
 
  
60 
 
  
 
Figure 17. Effects of diet-induced obesity on response to immune and targeted therapy. 
YUMM 3.1 tumors are resistant to PD1 in both A. control and B. DIO mice. Dabrafenib + 
trametinib combination results in rapid tumor elimination in both C. control and D. DIO mice.  
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Chapter 6: Summary and Future Directions 
 
Little is known about the clinical and therapeutic significance of obesity in melanoma.   
Our recent analysis of melanoma patients with clinically localized disease demonstrated that 
obesity is associated with worse outcomes in this population. (50)  My findings in a preclinical 
mouse melanoma subcutaneous model that diet-induced obesity increases melanoma tumor 
growth support these epidemiological associations. Further, the findings that diet-induced 
obesity leads to increased PI3K pathway activation and decreased tumor infiltrating 
immunocytes in this model suggest a biological basis for these findings.  
In contrast, my analysis of multiple large, independent cohorts of metastatic melanoma 
patients treated with contemporary targeted and immune therapies unexpectedly revealed that 
obesity was associated with significantly improved outcomes. In aggregate, these data support 
the presence of an “obesity paradox” across the spectrum of melanoma development, 
progression, and treatment response. Future work will be directed at understanding the 
biological basis of this paradox. In the subcutaneous mouse model, I did not observe 
differences in sensitivity to either targeted or immune therapy between obese and non-obese 
mice.  
There are several possible explanations for why the mouse findings on therapeutic 
response do not reflect those observed in humans. First, targeted and immune therapies are 
used in humans in the metastatic setting and the mouse experiments were conducted using a 
subcutaneous model with rapid tumor growth which does not allow time for the development of 
metastases. Second, the cell lines used have the advantage of being genetically relevant 
(BRAF-mutant) and as they are mouse cell lines are able to be used in immunocompetent 
models and thus this model can be used to test sensitivity to both MAPK pathway directed 
targeted therapies and immune therapies. However, these driver-mutation driven cell lines do 
not reflect the many stochastic mutations that occur in UV-induced human melanoma. 
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Therefore, they are poorly immunogenic as reflected by the complete lack of sensitivity to PD1 
inhibition with either diet. To address these issues, future studies will be conducted using 
metastatic models (tail-vein injection and survival surgery) in which BRAF-mutant cell lines are 
first irradiated to make them more immunogenic and a GEMM model to try to recapitulate the 
biology of a tumor that develops in the setting of obesity rather than being injected into a model 
of obesity.  
The other possibility for the discrepancy between the findings in humans and mice on 
the effect of obesity on sensitivity to therapy is that the associations observed in humans are 
spurious or artificial and represent a methodological issue rather than a true clinical 
association. Indeed, an “obesity paradox” has been demonstrated in other diseases but 
remains controversial for this reason. Possible methodological explanations for an obesity 
paradox include BMI as an imperfect measure of adiposity, confounding, selection bias, collider 
stratification bias, detection bias, or reverse causality.(75) However, several features of the 
current study suggest a biological role of adiposity in the survival advantage associated with 
obesity with metastatic melanoma.   In other diseases in which the obesity paradox has been 
observed, the survival advantage is often limited to overweight or only mildly obese patients. In 
several diseases, either the cancer or its treatment (i.e., chemotherapy) often cause weight 
loss, raising the possibility that this association may represent reversal causality.(75, 79) 
However, in the current study, there was a dose-dependent effect of BMI with modestly 
improved outcomes in overweight patients and strong, consistent associations in obese 
patients, and a nearly linear association between increasing BMI and PFS that extended to 
morbid obesity in the large D+T cohort. Further, the magnitude of the benefit seen with obesity, 
particularly in men, was equal to or greater than that seen in the registration trials that led to 
drug approval, and were seen in both test and validation cohorts for targeted and immune 
therapy, again supporting this association is unlikely to be spurious. I also accounted for the 
potential contribution of traditional prognostic factors and the use of concomitant medications 
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which may have anti-cancer activity, including metformin,(80, 81) statins,(82) beta blockers,(83) 
and aspirin.(84) To interrogate other potential causes of the observed differences, I examined 
rates of adverse events and available pharmacokinetic data (cobimetinib).  These analyses 
again showed no significant differences by BMI category, supporting that treatment tolerance 
and drug exposure are unlikely to explain the observed associations.  Differences in drug 
absorption are also an unlikely cause given that associations were seen with agents given 
orally at a fixed dose (targeted therapies) and with weight-based intravenous dosing 
(immunotherapies). As BMI was analyzed at a single time point (therapy initiation), I cannot rule 
out potential antecedent weight loss.  However, the BMI distribution of each cohort mirrored 
that of the general population,(55) with over 60% of patients classified as overweight or obese, 
and <2% underweight. ECOG PS and albumin levels (PD-1/PDL-1 cohort) also did not differ by 
BMI category.  Further, the targeted and immune therapy regimens examined are not usually 
associated with significant weight loss, which instead is more typical of chemotherapy, for 
which no associations with BMI were detected.  
The strength and consistency of these associations support the need for focused 
investigations into their biological basis. Although targeted and immune therapy are 
fundamentally different modalities, cross-talk between oncogenic signaling pathways and 
immune response has been implicated in response and resistance to both treatments in 
melanoma.(70, 71, 85-87) The tumor that develops in an obese individual could have a 
fundamentally different, more indolent, biology. In order to examine differences in molecular 
signaling pathways between obese and non-obese individuals, we will analyze the molecular 
data from the Melanoma The Cancer Genome Atlas (TCGA) by BMI. The TCGA project 
includes comprehensive molecular profiling (whole exome sequencing (WES), RNA 
sequencing, and DNA methylation) on 471 melanoma patients. Through collaborations with 
other institutions I have been able to get BMI data for about 2/3 of these patients. We will 
examine this data using an unbiased approach but also in a directed fashion to investigate 
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specific hypotheses. For example, whole exome sequencing data will be used to examine 
mutation burden as high mutation load has been associated with response to therapy as these 
tumors are more immunogenic.(88, 89) Alternatively, obesity may impact tumor gene 
expression profiles or epigenetics. As previously noted, PI3K pathway alterations have been 
found to mediate resistance to both targeted and immune therapy.(25, 28) Given the fact that, 
consistent with my initial hypothesis, obesity was found to increase PI3K pathway activation in 
the mouse model, it is necessary to assess the association of BMI and PI3K pathway in 
humans.   
Our approach of examining BMI associations in the melanoma TCGA is supported by a 
recent investigation in renal cell carcinoma (RCC) (another cancer in which an obesity paradox 
exists) where an analysis of BMI in the RCC TCGA found that alterations in fatty acid 
metabolism were associated with both high BMI and improved outcomes.(36)   Given emerging 
evidence implicating tumor metabolism in melanoma therapeutic response,(90-92) the 
relationship between tumor metabolism and clinical metabolic phenotype should also be 
explored in this disease.  
Alternatively, rather than impacting the tumor biology, obesity could impact the host 
response to the tumor, namely the immune response. The immune response is important to 
response not only to immune therapy, but to targeted therapy as well.(68, 93) The presence of 
tumor infiltrating lymphocytes (TILs) has long been recognized as a favorable prognostic factor 
in melanoma.(94) The initial melanoma TCGA analysis also identified an “immune signature” 
that was associated with improved survival.(95) Immune signatures have also been shown to 
correlate with response to both targeted and immune therapy.(68, 96, 97) The impact of obesity 
on tumor immunology is unknown. Obesity is a state of chronic inflammation and this is one of 
the key mechanisms linking obesity to increased risk of many malignancies.(37)  Obesity has 
been shown to impair response to vaccines and infections. However, the impact of obesity on 
anti-tumor immunology, and specifically in the setting of immune and targeted therapy, has not 
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been examined. Thus, I will examine the association of BMI with tumor infiltrating lymphocytes, 
and PD-L1 expression. In addition, I will examine BMI associations with peripheral blood cell 
populations and cytokines as these have also been associated with response to therapy.(98, 
99)   Given recent data implicating the microbiome in response to immunotherapy in 
melanoma(100-102), and prior evidence linking the microbiome with diet and obesity,(103) I will 
also examine the microbiome as a potential mediator of the observed effects. 
The striking differences in BMI and outcome associations by sex observed here suggest 
a potential hormonal mediator. Strong and consistent associations of higher BMI with improved 
outcomes was seen in male metastatic melanoma patients treated with both targeted and 
immune therapy while BMI was not associated with outcomes in females (Figure 18). Female 
sex has long been recognized as a predictor of improved outcomes in melanoma.(104, 105) 
Intriguingly, higher BMI seems to overcome the survival disadvantage among males, as the 
outcomes of obese males were similar to females of any BMI in the targeted therapy and 
immunotherapy cohorts, whereas normal BMI males had significantly inferior outcomes.   
Interrogation of TCGA data in other malignancies has demonstrated gender-specific 
differences in tumor biology, notably in metabolic and immune pathways.(57)  In melanoma, 
there is emerging evidence of differential tumor immunology by gender, with female melanoma 
patients exhibiting improved autologous tumor infiltrating lymphocytes (TIL) expansion(106) 
and increased tumor-antigen specific T cells compared to their male counterparts.(107) 
Preclinical data showed increased sensitivity to immune checkpoint blockade in female vs male 
mice, and pointed towards an estrogen-mediated functional reduction in T regulatory cells as 
the mechanism.(108) This data is consistent with the key role estrogen has been shown to play 
in sex differences in autoimmune disease and immune response to vaccination and 
infections.(109)  
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 Figure 18. Forest plot of hazard ratios for OS and PFS for high vs. low BMI by sex.  
Forest plots of hazard ratios for highest BMI group in comparison to normal BMI by cohort and 
sex for A. overall survival (OS) and B. progression-free survival (PFS) in males, and C. OS and 
D. PFS in females with metastatic melanoma receiving the indicated therapies. 
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Obesity leads to higher levels of circulating estrogen due to adipocyte aromatase 
conversion of androgens to estrogen compounds, though this effect is only significant in  men 
and postmenopausal females.(110) Combined with our findings, these data provide a strong 
rationale to examine the role of estrogen signaling on immune and/or tumor cells as a possible 
mediator of the gender-specific associations of obesity in this disease. Notably, although a 
randomized controlled trial of DTIC +/- tamoxifen, a selective estrogen receptor modulator, 
showed no benefit in metastatic melanoma patients overall, higher BMI in men was predictive 
of benefit from the addition of tamoxifen to chemotherapy, but not with chemotherapy 
alone.(111) Interestingly, the rationale for testing tamoxifen in melanoma was based on flawed 
studies showing high expression of estrogen receptor alpha (ERα) based on non-specific 
binding.(112) It has now been demonstrated that melanomas have very low (ERα) expression. 
However, melanoma does have high expression of estrogen-receptor beta (ERβ). (113, 114)  
ERβ has been shown to be anti-proliferative in other malignancies and recently in melanoma as 
well.(115-119)  In order to test this hypothesis, we will examine the TCGA data for correlations 
between BMI and sex and hormonal signaling and also perform functional testing of hormone 
signaling modulation. 
In conclusion, I have found a strong and consistent association of obesity with 
improved outcomes in patients with metastatic melanoma treated with targeted and immune 
therapies across multiple large independent cohorts. These associations appear to be driven 
predominantly by markedly improved outcomes in obese compared to normal BMI males. In 
contrast, I did not observe any significant associations of BMI with outcomes in female patients. 
As obesity is associated with worse outcomes in early stage melanoma, these findings support 
the presence of an obesity paradox in melanoma. The magnitude of the survival benefit 
associated with obesity in patients with metastatic melanoma support the need to include BMI 
as a stratification factor in the design of clinical trials. However, the implications for patient 
guidance at this point is unclear. While obesity at treatment initiation is associated with 
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improved outcomes, we do not know if deliberate change in weight after diagnosis can shift 
outcomes. It should be noted that we also do not know if deliberate weight changes can 
change the outcomes of other malignancies as well. Specifically, though it has now been very 
well-established that obesity is associated with worse outcomes in early stage breast cancer 
patients undergoing adjuvant therapy,(12) we currently lack prospective data examining the 
impact of deliberate weight loss after diagnosis on breast cancer patient outcomes.  There are 
currently ongoing randomized clinical trials assessing this question.  These types of trials are 
critical to establish whether BMI and outcome associations are reversible or whether these are 
non-reversible fixed biological effects, i.e. that the host metabolic phenotype has determined a 
tumor biology that cannot be changed.  
However, while in breast cancer we may lack data supporting that weight loss will 
decrease recurrence risk, there is abundant preclinical and correlative data supporting this 
strategy.(15, 16, 62, 73, 120-123) Moreover, most patients with early stage breast cancer, 
which has a very high cure rate, will ultimately die from other causes. The data linking obesity 
with increased risk of heart disease, stroke, and diabetes as well as second cancers is clear. 
Thus, even lacking the randomized clinical trial data supporting weight loss interventions in 
breast cancer survivors, there is compelling data both for supporting the rationale for trials 
testing this approach and even for supporting weight loss efforts pending these results in breast 
cancer patients as this will reduce their burden of other major causes of mortality and plausibly 
decrease their risk of breast cancer recurrence. 
In contrast, without an understanding of the mechanism underlying the association of 
obesity with improved outcomes in metastatic melanoma, preclinical evidence that obesity may 
increase cancer growth, and the impact of obesity on other potential causes of death, the 
epidemiological evidence presented in this thesis is not sufficient to support a weight gain 
intervention trial in metastatic melanoma patients. Instead, future research should be focused 
on understanding the biological basis for the association of obesity with improved outcomes so 
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that was can design rational therapeutic interventions (e.g. hormonal therapy, metabolic 
modulators) to improve the outcomes of all patients.  
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